AXNX News and Press, Axonics Modulation Technologies Inc. From 01/30/24

2024-01-30 20:00:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. This past year was incredibly challenging but Baron Discovery Fund returned 22.58% in ...

NEW YORK, NY / ACCESSWIRE / January 27, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Axonics, Inc. (NASDAQ: AXNX)'s s...

2024-01-15 15:49:19 ET More on Align Technology, DexCom, etc. Intuitive Surgical: Strong Pre-Announced Q4 - Time To Harvest The Gain, Initiate With 'Sell' Intuitive Surgical, Inc. (ISRG) JPMorgan Healthcare Conference Call Transcript Intuitive Surgical: Sustained Gro...

2024-01-10 18:01:36 ET Summary Boston Scientific Corporation has seen a steady recovery over the past decade, reaching all-time highs of $58 per share. The company has achieved solid middle- to higher-single digit organic revenue growth numbers, outperforming the market. Bosto...

2024-01-08 19:38:18 ET Shares of Axonics (NASDAQ: AXNX) were up 20.5% on Monday after the urology company agreed to be acquired by Boston Scientific (NYSE: BSX) . Boston Scientific shares were also up around half a percent on the news today. More specifically, Axonics ag...

2024-01-08 07:15:37 ET Axonics ( NASDAQ: AXNX ) shares jumped over 20% premarket on Monday after Boston Scientific ( NYSE: BSX ) announced a deal to acquire the med-tech firm for $71 per share in cash. Subject to customary closing conditions, the deal is expected...

Boston Scientific Announces Agreement to Acquire Axonics, Inc. PR Newswire Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction MARLBOROUGH, Mass. , Jan. 8, 2024 /PRNewswire/ -- Boston Scientific ...

Axonics, Inc. (Nasdaq: AXNX) today announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX) for $71 in cash per share, representing an equity value of approximately $3.7 billion. Axonics brings a complementary product portfolio to t...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023. “The ...

2024-01-07 17:18:52 ET More on Akoya Biosciences, Exact Sciences, etc. Guardant Health: Vast Market Opportunity, Challenging Valuation Illumina: The Divestiture Of Grail Could Unlock Significant Shareholder Value Illumina: Conditions Are Met For A Rebound Nan...